The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Mon., May. 30, 8:28 AM

Slide #15. Coherus BioSciences, Inc. Secondary Offering

Company: Coherus BioSciences, Inc. (NASDAQ:CHRS)
Date announced: 5/23/2016
Shares Offered: 3,500,000
Date of Pricing: 5/23/2016
Price Per Share: $18.00
Secondary Offering Details: Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced it has commenced an underwritten public offering of 3,500,000 shares of its common stock. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus expects to grant the underwriter a 30-day option to purchase up to an additional 525,000 shares of its common stock at the public offering price, less the underwriting discount. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 5/23- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced the pricing of its underwritten public offering of 3,500,000 shares of its common stock at a price to the public of $18.00 per share. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus has granted the underwriter a 30-day option to purchase up to an additional 525,000 shares of its common stock at the public offering price, less the underwriting discount.

Coherus BioSciences is a late-stage clinical biologics platform company, focused on the global biosimilar market. Co.'s clinical stage pipeline consists of two anti-inflammatory agents targeting: tumor necrosis factor (TNF), a substance in the body that is involved in the inflammatory response; and a long-acting form of granulocyte colony-stimulating factor (G-CSF). Co.'s main anti-TNF product candidate, CHS-0214, is being developed as an etanercept (Enbrel) biosimilar. Co.'s second anti-TNF product candidate, CHS-1420, is being developed as an adalimumab (Humira) biosimilar. Co.'s G-CSF product candidate, CHS-1701, is being developed as a pegfilgrastim (Neulasta) biosimilar.

CHRS SEC Filing Email Alerts Service

Open the CHRS Page at The Online Investor »

Company Name:  Coherus BioSciences Inc
Sector:  Biotechnology
Number of ETFs Holding CHRS:  17
Total Market Value Held by ETFs:  $19.98M
Total Market Capitalization:  $715.00M
% of Market Cap. Held by ETFs:  2.79%
 

Open the CHRS Page at The Online Investor (in a new window) »

May 30, 2016    8:28 AM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
89th percentile
(ranked higher than approx. 89% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.